title
stringlengths
1
1.19k
keywords
stringlengths
0
668
concept
stringlengths
0
909
paragraph
stringlengths
0
61.8k
PMID
stringlengths
10
11
4.3. Prediction Model
Currently, the usual management for overweight and obesity is done by calculating energy expenditure, establishing daily nutritional requirements, and performing caloric restriction, in addition to giving recommendations for lifestyle changes specific to each individual [
PMC10746100
4.4. BMI Percentage Loss Prediction Model Based on the MHP and LF Diets’ Methylation Data
BMI loss, weight loss
The model that predicts the percentage of BMI loss was made with a total methylation score that was constructed considering the MHP diet methylation score, in which the 15 CpG sites that were better associated with the reduction of BMI percentage were selected and 11 CpG sites for the LF diet. With this model, it was p...
PMC10746100
4.5. Strengths and Limitations
obesity
OBESITY
One of the main strengths of this pilot research is that it was carried out within the framework of a randomized clinical study in which more than 200 people were characterized. A methylation array was used to analyze around 850,000 methylation sites in each individual at baseline. Multiple methylation sites were ident...
PMC10746100
5. Conclusions
weight loss
This pioneer research demonstrates that DNA methylation is an individual characteristic that can be used to have greater precision in the nutritional treatment of BMI reduction. The model designed based on the methylation information through the linear mixed effect model allows predicting the percentage of BMI loss and...
PMC10746100
Supplementary Materials
The following supporting information can be downloaded at Click here for additional data file.
PMC10746100
Author Contributions
Conceptualization, F.I.M. and J.A.M.; methodology, F.I.M. and J.I.R.-B.; formal analysis, J.I.R.-B. and S.G.-C.; investigation, N.C.G.-Á. and S.G.-C.; resources, F.I.M. and J.A.M.; data curation, J.I.R.-B.; writing—original draft preparation, N.C.G.-Á.; writing—review and editing, F.I.M., J.I.R.-B., J.A.M. and S.G.-C.;...
PMC10746100
Institutional Review Board Statement
The study was performed in line with the guidelines of the Declaration of Helsinki and received approval by the Ethics Committee of the University of Navarra (ref. 132/2015).
PMC10746100
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.
PMC10746100
Data Availability Statement
Data will be available upon request by contacting the corresponding author.
PMC10746100
Conflicts of Interest
The authors declare that they have no conflict of interest.
PMC10746100
References
TNF-α, tumor necrosis
REGRESSION, INSULIN RESISTANCE, TUMOR NECROSIS
Flow chart of the participants who started and completed the intervention.Flow chart for the design of the prediction model based on DNA methylation.Flow chart for the selection of methylation sites (CpG) used for the prediction model.Prediction model of the percentage of BMI loss according to the total methylation sco...
PMC10746100
Background
obesity, NAFLD, appetite
OBESITY, NONALCOHOLIC FATTY LIVER DISEASE
Academic Editor: Cornelia Amălinei This trial assessed the effects of a calorie-restricted diet (CRD) with hydroxycitric acid (HCA) supplementation on appetite-regulating hormones, obesity indices, body composition, and appetite in women with nonalcoholic fatty liver disease (NAFLD).
PMC10356186
Methods
NAFLD
This study was carried out on 44 overweight/obese women with NAFLD. The patients were randomly assigned into two groups, namely, “
PMC10356186
Results
obesity
OBESITY
Forty patients completed the trial. At the end of the trial, although significant reductions were found in most of the studied obesity indices in the intervention group, there was only a significant decrease in waist circumference and waist-to-height ratio in the control group. Fat mass and muscle mass significantly d...
PMC10356186
Conclusion
weight loss diet
HCA plus weight loss diet could significantly reduce visceral adipose tissue without any significant changes in serum leptin and adiponectin levels.
PMC10356186
1. Introduction
NAFLD
NONALCOHOLIC FATTY LIVER DISEASE, CHRONIC LIVER DISEASE
Nonalcoholic fatty liver disease (NAFLD) is recognized as the most frequent chronic liver disease globally [
PMC10356186
2. Methods
PMC10356186
2.1. Study Design and Participants
LIVER DISEASES, COMPLICATIONS
In this single-blind, controlled, and randomized clinical trial, 142 female patients aged between 18 and 50 years and BMI = 27.5–40 kg/mThis paper is a part of already published studies [Those who were pregnant or lactating, had menopause, were alcohol drinker, or smoker, followed a weight-loss diet, and took dietary s...
PMC10356186
2.2. Sample Size
The sample size was determined based on the mean and standard deviation (SD) of serum leptin level at baseline reported by Vasques et al. [
PMC10356186
2.3. Randomization, Blinding, and Intervention
weight loss
The patients were randomly assigned to one of the two study groups (1 : 1). The randomized block procedure of size 4 was applied, and the sequence was generated using the random allocation software (RAS). Randomization was stratified by age (18–35 yrs. To assess habitual diet for each subject, a validated 169-item food...
PMC10356186
2.4. Measures and Assessments
To assess dietary intakes, the subjects completed three food records (two nonconsecutive weekdays and a weekend) and data on food intake were analyzed by Nutritionist IV software (First Databank, USA) modified for Iranian foods. Appetite status was assessed using a validated 6-item questionnaire based on 100 mm visual ...
PMC10356186
2.5. Statistical Analysis
Data analysis was conducted using SPSS 25.0 software (SPSS Inc., Chicago, IL, USA). The Kolmogorov–Smirnov test was used for checking the normality of the data distribution. Between-group comparisons at baseline were tested using the independent samples
PMC10356186
3. Results
Forty patients completed the trial. Appetite status assessed by VAS is presented in Changes in serum levels of leptin and adiponectin over the trial are presented in
PMC10356186
4. Discussion
obesity
OBESITY
Results of this trial showed significant reductions in obesity indices and total and visceral fat without any significant change in serum leptin and adiponectin levels. Although energy and macronutrient intakes decreased in both groups, greater reductions were observed in the control group than in the intervention grou...
PMC10356186
5. Conclusion
NAFLD, LCD
OBESE
It is concluded that HCA plus LCD in obese women with NAFLD could significantly reduce visceral adipose tissue without any significant changes in serum leptin and adiponectin levels.
PMC10356186
Acknowledgments
The authors sincerely thank the patients who participated in this clinical trial. The authors would like to appreciate the cooperation of the Clinical Research Development Unit of Imam Reza General Hospital, Tabriz, Iran, in conducting this research. This study was written based on the data obtained from the M.Sc. Thes...
PMC10356186
Data Availability
The datasets used and analyzed during the current study are not publicly available due to our center's patient confidentiality policies, but they are available from the corresponding author on reasonable request.
PMC10356186
Conflicts of Interest
The authors declare that they have no conflicts of interest.
PMC10356186
Authors' Contributions
NAFLD, Obesity, obesity, skeletal muscle mass, FM, HT
OBESITY, NONALCOHOLIC FATTY LIVER DISEASE, OBESITY
The authors' responsibilities were as follows: MEM contributed to the conception of the article; SA, SNG, and HT wrote the original paper; MEM contributed to the statistical analysis; and MEM and HT contributed to the final revision of the manuscript. All authors read and approved the final version of the manuscript.Fl...
PMC10356186
1. Introduction
obese, endotoxemia, cancer, weight reduction, metabolic diseases, overweight, post-prandial endotoxemia
METABOLIC DISEASES, CANCER, OBESE, ENDOTOXEMIA
Sugar-rich diets, but also the use of intense sweeteners, may alter intestinal barrier function. Here, we assessed the effect of sucrose and sucralose on post-prandial endotoxemia in a randomized placebo-controlled single-blinded crossover-designed study. Following a 2-day standardization of their diet, healthy men and...
PMC10537596
2. Materials and Methods
PMC10537596
2.1. Study Participants
post-prandial endotoxemia
This randomized controlled prospective human intervention study in crossover design was approved by the Ethics Committee of the University of Vienna (reference number: 00585) and was carried out in accordance with the ethical standards laid down in the Declaration of Helsinki. Originally, it was planned to investigate ...
PMC10537596
2.2. Intervention Study
The study design is summarized in
PMC10537596
2.3. Anthropometry, Blood Pressure and Metabolic Parameters
BLOOD
At the beginning and over the course of the study, anthropometric data and blood pressure were determined. Blood lipids were measured using a commercially available measuring instrument (Swiss Point of Care, LJ IJsselstein, The Netherlands). Blood sugar levels were assessed in capillary blood obtained from the fingerti...
PMC10537596
2.4. Bacterial Endotoxin
To assess the effect of the standardized nutrition as well as of the different beverages on bacterial endotoxin levels in plasma of participants over time, a limulus amebocyte lysate assay was used (Charles River, Ecully, France) as detailed previously [
PMC10537596
2.5. Caco-2 Cells In Vitro Experiments
Differentiated Caco-2 cells (ACC 169, DSMZ, Braunschweig, Germany) were grown in trans-wells by using DMEM medium containing 10% fetal bovine serum (Pan-Biotech GmbH, Aidenbach, Germany) and 100 µg/mL streptomycin and 100 U/mL penicillin (Pan-Biotech GmbH, Aidenbach, Germany) in a 5% carbon dioxide atmosphere. After re...
PMC10537596
2.6. Enzyme-Linked Immunosorbent Assay (ELISA)
Intestinal fatty acid
Intestinal fatty acid binding protein (iFABP) concentrations were analyzed in cell culture supernatant of the apical side of the Caco-2 cell trans-well model using a commercially available ELISA kit (Bio-Techne Corp., Minneapolis, MN, USA).
PMC10537596
2.7. Ex Vivo Everted Gut Sac Experiments and Xylose Permeation Measurement
SMALL INTESTINE
Small intestine (
PMC10537596
2.8. Statistical Analysis
Data are presented as means ± SEM. To test for normality, a Shapiro–Wilk normality test was performed. Grubb’s test was used before statistical analysis to identify outliers. To assess the effects between two paired groups, a paired
PMC10537596
3. Results
PMC10537596
3.1. Baseline Characteristics and Nutritional Standardization
corona infections
Of the 18 normal-weight, healthy men and women enrolled in the study, 11 participants finished the study and were analyzed. Seven participants did not start the study as they dropped out of the study due to corona infections (
PMC10537596
3.2. Effect of an Acute Intake of Sucralose, Sucrose and an Isocaloric Combination of Sucralose and Maltodextrin, Respectively, on Post-Prandial Bacterial Endotoxin Levels in Blood
After the intake of the sucrose-sweetened beverage, plasma endotoxin levels increased significantly when compared with baseline levels (120 min: +~45%, 180 min: +~36% compared with baseline,
PMC10537596
3.3. Effect of Sucralose and Sucrose on Bacterial Endotoxin Permeation and Protein Levels of iFABP in Differentiated Caco-2 Cells
To further assess if the increase in bacterial endotoxin levels found after the intake of sucrose was related to changes in intestinal barrier function and to compare these effects with those of sucralose, a model of the intestinal barrier, e.g., differentiated Caco-2 cells grown on trans-well inserts was employed in w...
PMC10537596
3.4. Effect of Sucralose and Sucrose on Markers of Intestinal Barrier Function in Small Intestinal Everted Tissue Sacs of C57BL/6J Mice
When challenging small intestinal everted tissue sacs with sucrose, the permeation of xylose significantly increased compared with tissue sacs only incubated with 1× Krebs–Henseleit buffer. In contrast, the intestinal permeation of xylose was not altered when tissue sacs were challenged with sucralose (
PMC10537596
4. Discussion
weight gain
DISEASES
Intense sweeteners widely used in human nutrition as substitutes for sugars like sucrose or high-fructose corn syrup may have beneficial effects with regard to body weight gain and the development of some non-communicable diseases [In line with our previous findings [
PMC10537596
Limitations
MASLD, metabolic abnormalities
TYPE 2 DIABETES
Our study is not without limitations that need to be considered when interpreting the data. A major limitation of our study is the sample size of only 11 subjects and the focus on young, healthy adults. The results might differ in a larger cohort and in another age group as well as in subjects with metabolic abnormalit...
PMC10537596
5. Conclusions
intestinal barrier dysfunction
METABOLIC DISEASES, INTESTINAL BARRIER DYSFUNCTION, TYPE 2 DIABETES
In summary, our data suggest that the intake of a sucralose-sweetened beverage in a physiological amount, e.g., 1 L, has no effect on intestinal barrier function in healthy young adults. To our knowledge, this is the first study which examines the effect of an acute intake of sucralose on endotoxin levels in healthy, n...
PMC10537596
Author Contributions
Conceptualization, I.B.; Formal analysis, R.S.; Funding acquisition, I.B. and A.B.; Investigation, R.S., V.S. and A.B.; Visualization, R.S. and A.B.; Writing—original draft, R.S., I.B. and A.B., Writing—review & editing, R.S., V.S., I.B. and A.B. All authors have read and agreed to the published version of the manuscri...
PMC10537596
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University of Vienna (protocol code 00585, 13 January 2021).
PMC10537596
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
PMC10537596
Data Availability Statement
Data are made available upon reasonable request.
PMC10537596
Conflicts of Interest
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analysis or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
PMC10537596
References
Design of the randomized controlled single-blinded crossover-designed human intervention study.Effect of a beverage containing either sucrose, sucralose or sucralose + maltodextrin on bacterial endotoxin levels in peripheral blood 60, 120 and 180 min after the consumption of the respective beverage. Values are means ± ...
PMC10537596
Purpose
fracture, weight loss, bone loss
BONE LOSS
Intentional weight loss has been shown to increase bone loss short term but the long-term effects are not known. Data from the Look AHEAD clinical trial shows that a long term intentional weight loss intervention was associated with greater bone loss at the hip in men.Intentional weight loss has been shown to increase ...
PMC10348976
Methods
weight loss, bone loss
BONE LOSS
Data from a subgroup from the Look AHEAD (LA) multicenter, randomized clinical trial was used to evaluate whether a long term intentional weight loss intervention would increase bone loss. In a preplanned substudy, BMD was assessed at 5 of the 16 LA clinical centers using dual-energy X-ray absorptiometry at baseline, y...
PMC10348976
Results
At year 8, bone density loss (%) was greater in the Intensive Lifestyle Intervention (ILI) group compared with the control group (DSE) for the femoral neck (
PMC10348976
Conclusion
fracture, weight loss
BONE LOSS
Long term intentional weight loss was associated with greater bone loss at the hip in men. These results taken with the previously published Look AHEAD data from the entire clinical trial showing increased frailty fracture risk with weight loss in the ILI group suggest that when intentional weight loss is planned, cons...
PMC10348976
Trial Registration
Clinicaltrials.gov Identifier: NCT00017953. June 21, 2001
PMC10348976
Supplementary Information
The online version contains supplementary material available at 10.1007/s11657-023-01303-0.
PMC10348976
Keywords
PMC10348976
Introduction
overweight / obesity, DM, weight loss, diabetes
DIABETES
Among the US population, it is estimated that over 34 million people have diabetes and this risk increases with age and increasing body mass index (BMI) [Therefore, the purpose of this analysis is to examine whether this long term intentional weight loss intervention resulted in sustained bone density loss, beyond four...
PMC10348976
Methods
DM, Fracture, fracture
The Look AHEAD randomized clinical trial involved 16 clinical sites across the US (Clinicaltrials.gov Identifier: NCT00017953). The methods and baseline characteristics of the study population have been published and the protocol is available (Intervention curricula for both ILI and DSE were developed centrally and hav...
PMC10348976
Dual-energy X-ray absorptiometry (DXA) substudy
SECONDARY
Look AHEAD was also designed to examine secondary outcomes including areal BMD changes. In a preplanned substudy, total hip, lumbar spine, and whole body DXA scans were obtained at baseline, year 1, year 4, year 8, and at the observational visit which occurred 12.6 – 16.3 years after randomization (year 12–16) at five ...
PMC10348976
Fracture ascertainment
fracture, fractures, primary fracture
EVENTS, SECONDARY
During annual visits and telephone calls every 6 months, staff members who were unaware of study-group assignments (blinded) queried participants about all medical events and hospitalizations including incident fractures. Hospital and other records such as outpatient medical records and x-ray reports were reviewed for ...
PMC10348976
Statistical analysis
bone loss
BONE LOSS
Baseline characteristics were summarized with means and standard deviations for continuous variables, and frequencies and percents for categorical variables, stratified by randomization arm and gender. Comparisons between randomization arms were made with t-tests or chi-square tests of association as appropriate with a...
PMC10348976
Discussion
obesity, fracture, weight loss, bone loss
OSTEOPOROTIC FRACTURES, OBESITY, SECONDARY, BONE LOSS
In the Look AHEAD clinical trial in persons with overweight and obesity and with DM, we previously found that an intensive lifestyle intervention that resulted in intentional long term weight loss and improved fitness increased the risk of frailty fracture [Our finding of increased bone loss with weight loss is consist...
PMC10348976
Conclusion
fracture, weight loss
BONE LOSS
Long term intentional weight loss was associated with greater bone loss at the hip in men long term and in women in the shorter term. These results taken with the previously published Look AHEAD fracture data from the entire clinical trial showing increased frailty fracture risk in the ILI group with intentional weight...
PMC10348976
Funding
Bartter, Johnson & Johnson Company, Digestive, Diabetes
LUNG, KIDNEY DISEASES, DIABETES, BLOOD, HEART, DISEASE
Funded by the National Institutes of Health through cooperative agreements with the National Institute on Aging: AG058571 and National Institute of Diabetes and Digestive and Kidney Diseases: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK...
PMC10348976
Data Availability
Digestive, Diabetes
KIDNEY DISEASES, DIABETES
Data that support the findings from the Look AHEAD trial (Action for Health in Diabetes) can be accessed through application to the National Institute of Diabetes and Digestive and Kidney Diseases; NIDDK Central Repository: 
PMC10348976
Declarations
PMC10348976
Ethical approval
All procedures performed in the Look AHEAD study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
PMC10348976
Informed consent
Informed consent was obtained from all individual participants included in the study.
PMC10348976
Competing interests
Andrea Anderson
SCHWARTZ
The authors have disclosed the following financial and non-financial competing interests and funding.Karen C. Johnson, MD, MPH – The author declares that they have no conflict of interest.Andrea Anderson, MS—The author declares that they have no conflict of interest.Kristen M. Beavers, PhD—The author declares that they...
PMC10348976
Human and animal rights
The Look AHEAD study was approved by the appropriate institutional research ethics committees and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
PMC10348976
References
PMC10348976
Background
cancer, Inflammation
CANCER, DISEASE, MALIGNANCIES, INFLAMMATION
Edited by: Luisa Giaccone, University of Turin, ItalyReviewed by: Elisabetta Metafuni, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy; Sakhila Ghimire, University Medical Center Regensburg, GermanyThis article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in I...
PMC9974829
Methods
comorbidity
DISEASE
Analyses were conducted retroactively on a cohort of 185 consecutive patients who underwent haploidentical hematopoietic stem cell transplantation (haplo-HSCT) at Wuhan Union Medical College Hospital during the period from February 2017 to January 2019. Of these patients, 129 were randomly assigned to the training coho...
PMC9974829
Results
Comorbidity
DISEASE
Patients were separated into low and high CAR groups using a cutoff of 0.087, which independently predicted overall survival (OS). Based on risk factors, CAR, the Disease Risk Index(DRI), and the Hematopoietic Cell Transplantation–specific Comorbidity Index(HCT-CI), the nomogram was developed to predict OS. The C-index...
PMC9974829
Conclusion
CAR is an independent prognostic indicator for haplo-HSCT outcomes. Higher CAR was related to worse clinicopathologic characteristics and poorer prognoses in patients underwent haplo-HSCT. This research provided an accurate nomogram for predicting the OS of patients following haplo-HSCT, illustrating its potential clin...
PMC9974829
Introduction
hematologic malignancies, Comorbidity
DISEASE, COMPLICATION, HEMATOLOGIC MALIGNANCIES, MALNUTRITION, DISEASE CHARACTERISTIC, COMPLICATIONS
One of the most promising treatments for patients with hematologic malignancies is allogeneic hematopoietic stem cell transplantation (allo-HSCT) (It can be challenging to select patients who will benefit from HSCT because survival after transplantation can vary greatly and rely on many factors. Various factors, includ...
PMC9974829
Materials and methods
PMC9974829
Study patients
malignant hematologic disease
This research comprised all consecutive adult patients (aged >18 years) with malignant hematologic disease who underwent haplo-HSCT within the period of February 2017 to January 2019 at Wuhan Union Medical College Hospital. All patients who received haplo-HSCT as their initial allogeneic transplant were included in the...
PMC9974829
Definitions
inflammation
INFLAMMATION
All data were collected directly within 10 days of the allo-HSCT conditioning regimen to assess the inflammatory and nutritional status before transplantation. We investigated CRP as a marker of inflammation and albumin as an indicator of nutritional status. CAR was counted by dividing the serum CRP level by the serum ...
PMC9974829
CRP and albumin level measurement
5 ml of cubital vein whole blood was extracted from all patients in the morning on an empty stomach. Serum CRP level measurements were included in the routine clinical tests using an automated biochemical analyzer
PMC9974829
Donor selection, transplant regimens, and GVHD prophylaxis and treatment
Donor selection method in accordance with the non-HLA system (
PMC9974829
Development of a prognostic model
REGRESSION
In total, 185 patients were randomized into two groups (training and validation cohorts) based on a ratio of 7 to 3. the following medical characteristics were evaluated to identify the predictive factors of survival in the training cohort: age at HSCT, sex, DRI, HCT-CI, CAR, donor–recipient relationship, donor–recipie...
PMC9974829
Model validation and clinical use
The predictive capability of the nomogram was evaluated by assessing discrimination power and calibration in the training, validation, and entire cohorts. The concordance index (C-index) was computed to evaluate the discriminative ability of the novel nomogram in all cohorts. A higher C-index suggests superior capabili...
PMC9974829
Statistical analysis
Categorical features were presented as counts and proportions and examined by the chi-squared test. Continuously parameterized characteristics were reported as the median and interquartile range (IQR), and comparisons of continuous variables between cohorts were determined using the Mann–Whitney U test. In these tests,...
PMC9974829
Results
PMC9974829
Optimal cutoff of CAR for predicting all-cause mortality following haplo-HSCT
death
The median CAR among 185 patients was 0.087 (range, 0.00667–2.67352). With all-cause patient death as the outcome variable, a 3-year time-dependent ROC curve was created, and the maximum Youden index for OS was utilized to determine the optimal cutoff. The optimal cutoff of CAR was finally regarded as 0.109. Patients w...
PMC9974829
Baseline clinical features of the research cohort
isohemagglutinins
The baseline clinical features of the training and validation cohorts are depicted in Patients’ baseline features.Minor ABO mismatch demonstrated the donor had isohemagglutinins against the recipient’s red blood cells, including the following blood group combinations: O (donor) into A, B, or AB (recipient); A or B (don...
PMC9974829
Construction of the novel nomogram of OS
REGRESSION
In univariate analysis, OS was related to DRI (P < 0.001), HCT-CI (P = 0.038), and CAR (P < 0.001). In multivariate Cox regression analysis, DRI (P < 0.001), HCT-CI (P = 0.011), and CAR (P =0.017) were independent predictors of OS following haplo-HSCT (Univariate and multivariate Cox analysis for OS in patients with ha...
PMC9974829
Validation of the novel nomogram
The C-indices of the novel nomogram for 3-year OS in the training cohort by bootstrap resampling was 0.671 (95% CI = 0.5923–0.7496). Meanwhile, it was found that the calibration plot displayed good similarity between the predicted and actual survival rates (Calibration curves for predicting 3-year OS in training cohort...
PMC9974829
Comparison of the nomograms and DRCI
Comparisons between DRCI and the nomograms were also conducted. For the three cohorts shown in the figure, the AUCs of the nomogram were greater than those of DRCI [0.715 (95% CI:0.617–0.812) Area under the ROC curves of nomogram and DRCI of OS in training cohort Comparison of the decision curves between the nomogram a...
PMC9974829
Discussion
acute myeloid leukemia, tumor, inflammation, Comorbidity, malnutrition
ACUTE MYELOID LEUKEMIA, CANCER PROGRESSION, TUMOR, PROLIFERATION, INFLAMMATION, DISEASE, INVASIVE CANCER, MYELODYSPLASTIC SYNDROMES, MALNUTRITION, HEMATOLOGICAL MALIGNANCY
DRI, HCT-CI, and CAR were the components of the developed OS nomogram. Previous studies using multivariate analysis also demonstrated significant associations between these prognostic variables and OS in patients following haplo-HSCT. Our results reconfirmed the conclusions of these investigations. In this research, we...
PMC9974829
Conclusion
To our knowledge, none of the existing scoring systems considers the pre-transplant inflammatory and nutritional status. This is the first study to demonstrate the predictive power of pre-transplant CAR for survival outcomes following haplo-HSCT. Compared with DRCI, the nomogram incorporating CAR displayed substantiall...
PMC9974829
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
PMC9974829
Ethics statement
The studies involving human participants were reviewed and approved by the Ethics Committee of Tongji Medical College of Huazhong University. The patients/participants provided their written informed consent to participate in this study.
PMC9974829
Author contributions
KW collected, analyzed the data, and wrote the paper. XJ and ZX researched the literature and revised the paper. All authors contributed to the article and approved the submitted version.
PMC9974829
Acknowledgments
The authors of this study would like to thank all the study participants for their contributions.
PMC9974829